Pfizer's Lyme vaccine achieves 73% efficacy in trials
Pfizer has announced that its experimental vaccine for Lyme disease demonstrates an efficacy of up to <strong>73%</strong>. However, concerns have been raised regarding the low number of cases in the trial, casting doubt on the vaccine's broader effectiveness.